PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis.

In addition, as demonstrated by a long-term study, PCSK9 antibody in the L-IFPTA + vaccine group achieved peak titers at week 8 and stayed constant until week 12, then exhibited a decreasing trend ( Figure 2 A ).

also in 47,180 other papers

The L-IFPTA + vaccine resulted in an increasing trend of plasma TC and LDL-C in hypercholesterolemic C57BL/6 mice, at week 8 ( Figure 3 ).

also in 63,971 other papers